Serological responses and clinical outcome after vaccination of mares and foals with equine herpesvirus type 1 and 4 (EHV-1 and EHV-4) vaccines

Veterinary Microbiology

Volumn 160, Issue 1-2, 2012, Pages 9-16

  Bresgen, Claudia ^a,b   Lämmer, Marc ^b   Wagner, Bettina ^c   Osterrieder, Nikolaus ^a   Damiani, Armando Mario ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b Gestüt Lewitz ^*  (Germany)

^c Department of Molecular Biology and Genetics   (United States)

Author keywords

Abortion; EHV 1; Serology; Vaccination

Indexed keywords

DUVAXYNEHV; EQUINE HERPESVIRUS TYPE 1 VACCINE; EQUINE HERPESVIRUS TYPE 4 VACCINE; HERPES VACCINE; IMMUNOGLOBULIN G; LIVE VACCINE; MODIFIED LIVE VIRUS VACCINE; PREVACCINOL; UNCLASSIFIED DRUG;

ABORTION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EQUINE HERPESVIRUS TYPE 1; EQUINE HERPESVIRUS TYPE 4; FEMALE; FOAL; GESTATIONAL AGE; HERPES VIRUS; HUMORAL IMMUNITY; MARE; NONHUMAN; SEROLOGY; VACCINATION;

ABORTION, VETERINARY; ANIMALS; ANTIBODIES, VIRAL; FEMALE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 1, EQUID; HERPESVIRUS 4, EQUID; HERPESVIRUS VACCINES; HORSE DISEASES; HORSES; IMMUNOGLOBULIN ISOTYPES; PREGNANCY; VACCINATION; VACCINES, INACTIVATED;

ANIMALIA; EQUID HERPESVIRUS 1; EQUID HERPESVIRUS 4; EQUIDAE;

EID: 84867022725     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2012.04.042     Document Type: Article

References (29)

1. Allen G., Powell D. Equine herpesvirus neurological disease in the USA and United Kingdom. Equine Dis. Q. 2003, 12:2-3.
2. Allen G., Yeargan M., Costa L.R., Cross R. Major histocompatibility complex class I-restricted cytotoxic T-lymphocyte responses in horses infected with equine herpesvirus 1. J. Virol. 1995, 69:606-612.
3. Allen G.P., Bryans J.T. Molecular epizootiology, pathogenesis, and prophylaxis of equine herpesvirus-1 infections. Prog. Vet. Microbiol. Immunol. 1986, 2:78-144.
4. Burki F., Rossmanith W., Nowotny N., Pallan C., Mostl K., Lussy H. Viraemia and abortions are not prevented by two commercial equine herpesvirus-1 vaccines after experimental challenge of horses. Vet. Q. 1990, 12:80-86.
5. Cardwell J., Smith K., Newton R., Blunden T., Bestbier M., Whitwell K. EHV paralytic disease in the south of England. Vet. Rec. 2003, 152:441-442.
6. Edington N., Bridges C.G., Patel J.R. Endothelial cell infection and thrombosis in paralysis caused by equid herpesvirus-1: equine stroke. Arch. Virol. 1986, 90:111-124.
7. Foote C.E., Gilkerson J.R., Whalley J.M., Love D.N. Seroprevalence of equine herpesvirus 1 in mares and foals on a large Hunter Valley stud farm in years pre- and postvaccination. Aust. Vet. J. 2003, 81:283-288.
8. Foote C.E., Love D.N., Gilkerson J.R., Wellington J.E., Whalley J.M. EHV-1 and EHV-4 infection in vaccinated mares and their foals. Vet. Immunol. Immunopathol. 2006, 111:41-46.
9. Foote C.E., Love D.N., Gilkerson J.R., Whalley J.M. Serological responses of mares and weanlings following vaccination with an inactivated whole virus equine herpesvirus 1 and equine herpesvirus 4 vaccine. Vet. Microbiol. 2002, 88:13-25.
10. Foote C.E., Love D.N., Gilkerson J.R., Whalley J.M. Detection of EHV-1 and EHV-4 DNA in unweaned Thoroughbred foals from vaccinated mares on a large stud farm. Equine Vet. J. 2004, 36:341-345.
11. Goehring L.S., Wagner B., Bigbie R., Hussey S.B., Rao S., Morley P.S., Lunn D.P. Control of EHV-1 viremia and nasal shedding by commercial vaccines. Vaccine 2010, 28:5203-5211.
12. Goodman L.B., Loregian A., Perkins G.A., Nugent J., Buckles E.L., Mercorelli B., Kydd J.H., Palu G., Smith K.C., Osterrieder N. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog. 2007, 3(11):e160.
13. Goodman L.B., Wagner B., Flaminio M.J., Sussman K.H., Metzger S.M., Holland R., Osterrieder N. Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine 2006, 24:3636-3645.
14. Heldens J.G., Hannant D., Cullinane A.A., Prendergast M.J., Mumford J.A., Nelly M., Kydd J.H., Weststrate M.W., van den Hoven R. Clinical and virological evaluation of the efficacy of an inactivated EHV1 and EHV4 whole virus vaccine (Duvaxyn EHV1,4). Vaccination/challenge experiments in foals and pregnant mares. Vaccine 2001, 19:4307-4317.
15. Mayr A., Pette J. 1st experiments concerning the vaccination of horses against rhino-pneumonia (viral abortion of mares) with a live vaccine from cell cultures. Bull. Off. Int. Epizoot. 1968, 70(1):133-140.
16. Mayr A., Pette J., Petzoldt K., Wagener K. Studies on the development of a live vaccine against rhinopneumonitis (mare abortion) of horses. Zentralbl. Veterinarmed. B 1968, 15(3):406-418.
17. OIE Manual for Terrestial Animals, 2008. Equine Rhinopneumonitis, (Chapter 2.5.9). http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.05.09_EQUINE_RHINO.pdf.
18. Paillot R., Daly J.M., Juillard V., Minke J.M., Hannant D., Kydd J.H. Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. Vaccine 2005, 23:4541-4551.
19. Patel J.R., Foldi J., Bateman H., Williams J., Didlick S., Stark R. Equid herpesvirus (EHV-1) live vaccine strain C147: efficacy against respiratory diseases following EHV types 1 and 4 challenges. Vet. Microbiol. 2003, 92:1-17.
20. Patel J.R., Heldens J. Equine herpesviruses 1 (EHV-1) and 4 (EHV-4)-epidemiology, disease and immunoprophylaxis: a brief review. Vet. J. 2005, 170:14-23.
21. Rosas C.T., Goodman L.B., von Einem J., Osterrieder N. Equine herpesvirus type 1 modified live virus vaccines: quo vaditis?. Expert Rev. Vaccines 2006, 5:119-131.
22. Rudolph J., Osterrieder N. Equine herpesvirus type 1 devoid of gM and gp2 is severely impaired in virus egress but not direct cell-to-cell spread. Virology 2002, 293:356-367.
23. Rudolph J., Seyboldt C., Granzow H., Osterrieder N. The gene 10 (UL49.5) product of equine herpesvirus 1 is necessary and sufficient for functional processing of glycoprotein M. J. Virol. 2002, 76:2952-2963.
24. Sheoran A.S., Lunn D.P., Holmes M.A. Monoclonal antibodies to subclass-specific antigenic determinants on equine immunoglobulin gamma chains and their characterization. Vet. Immunol. Immunopathol. 1998, 62(2):153-165.
25. Smith K.C., Borchers K. A study of the pathogenesis of equid herpesvirus-1 (EHV-1) abortion by DNA in situ hybridization. J. Comp. Pathol. 2001, 125:304-310.
26. Smith K.C., Mumford J.A., Lakhani K. A comparison of equid herpesvirus-1 (EHV-1) vascular lesions in the early versus late pregnant equine uterus. J. Comp. Pathol. 1996, 114:231-247.
27. van Maanen C., Flore P.H., Minke J., Bruin G. Immune response of foals after vaccination against EHV-1/EHV-4 and persistence of maternal antibodies. Equine Infectious Diseases VII: Proceedings of the Seventh International Conference 1994, 351-352. R and W Publications Ltd., Newmarket, United Kingdom. H. Nakajima, W. Plowright (Eds.).
28. Whalley J.M., Robertson G.R., Davison A.J. Analysis of the genome of equine herpesvirus type 1: arrangement of cleavage sites for restriction endonucleases EcoRI, BglII and BamHI. J. Gen. Virol. 1981, 57:307-323.
29. Wilson W.D. Equine herpesvirus 1 myeloencephalopathy. Vet. Clin. North Am. Equine Pract. 1997, 13:53-72.